Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback